AstraZeneca Sales Force Restructuring Boosts Operating Profit, Not Sales
AstraZeneca's efforts to restructure its EU sales force have helped the company improve its margins
You may also be interested in...
Maintaining a stellar credit rating is not a constraint on how much Johnson & Johnson is willing to spend on acquisitions, Chief Financial Officer Dominic Caruso said during the company's April 15 first quarter earnings call
AstraZeneca expects its settlement agreement with Ranbaxy ending Nexium (esomeprazole) patent infringement litigation will win a nod of approval from the Federal Trade Commission
AstraZeneca is looking to establish Seroquel XR, the sustained-release line extension of its atypical antipsychotic quetiapine, by adding unique indications rather than pushing to switch patients from immediate-release Seroquel